Epalrestat, an AKR1B1 inhibitor, significantly suppresses cancer stem cell properties, tumorigenicity, and metastasis of basal-like breast cancer cells through regulating the NF-κB pathway [58]. The gene discussed is AKR1B1; the disease is breast carcinoma.